Human and Murine Toll-like Receptor-Driven Disease in Systemic Lupus Erythematosus.
Susannah von HofstenKristin Andreassen FentonHege Lynum PedersenPublished in: International journal of molecular sciences (2024)
The pathogenesis of systemic lupus erythematosus (SLE) is linked to the differential roles of toll-like receptors (TLRs), particularly TLR7, TLR8, and TLR9. TLR7 overexpression or gene duplication, as seen with the Y-linked autoimmune accelerator ( Yaa ) locus or TLR7 agonist imiquimod, correlates with increased SLE severity, and specific TLR7 polymorphisms and gain-of-function variants are associated with enhanced SLE susceptibility and severity. In addition, the X-chromosome location of TLR7 and its escape from X-chromosome inactivation provide a genetic basis for female predominance in SLE. The absence of TLR8 and TLR9 have been shown to exacerbate the detrimental effects of TLR7, leading to upregulated TLR7 activity and increased disease severity in mouse models of SLE. The regulatory functions of TLR8 and TLR9 have been proposed to involve competition for the endosomal trafficking chaperone UNC93B1. However, recent evidence implies more direct, regulatory functions of TLR9 on TLR7 activity. The association between age-associated B cells (ABCs) and autoantibody production positions these cells as potential targets for treatment in SLE, but the lack of specific markers necessitates further research for precise therapeutic intervention. Therapeutically, targeting TLRs is a promising strategy for SLE treatment, with drugs like hydroxychloroquine already in clinical use.
Keyphrases
- toll like receptor
- inflammatory response
- systemic lupus erythematosus
- immune response
- nuclear factor
- disease activity
- randomized controlled trial
- multiple sclerosis
- transcription factor
- climate change
- cell proliferation
- oxidative stress
- mouse model
- gene expression
- induced apoptosis
- signaling pathway
- dna methylation
- heat shock
- genome wide analysis